{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_names_stdName in Standardized Name (approximate match)
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
HS-173 is a potent PI3Kα inhibitor with IC50 of 0.8 nM. HS-173 inhibited the PI3K signaling pathway, and showed anti-proliferative effects on cancer cells. Also, HS-173 induced cell cycle arrest at the G(2)/M phase and apoptosis. In addition, HS-173 decreased the expression HIF-1α and VEGF which play an important role in angiogenesis. This effect was confirmed by the suppression of tube formation and migration assay in vitro. Furthermore, HS-173 diminished blood vessel formation in the Matrigel plug assay in mice. Therefore, HS-173 is considered as a novel drug candidate to treat cancer patients.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
CZC24832 is a highly selective and potent phosphoinositide 3-kinase γ (PI3Kγ) inhibitor. It dempnstrated efficacy in in vitro and in vivo models of inflammation.
![Structure of 4-(3-(1-(But-2-ynoyl)pyrrolidin-2-yl)-8-hydroxyimidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, (S)-](/img/6f6aa779-bef3-4621-a690-faff6bb0038c.svg?size=200&context=zqezipdxpr)
![Structure of 4-(9-(1-(But-2-ynoyl)pyrrolidin-2-yl)-4-methyl-2-oxo-2H-imidazo[5',1':3,4]pyrazino[1,2-a]pyrimidin-11-yl)-N-(pyridin-2-yl)benzamide, (S)-](/img/b33b77df-8d82-46ed-8a40-408cdd280193.svg?size=200&context=zqezipdxpr)
